ALX Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Shelly
ALX Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Shelly
ALX Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Pons Jaume
ALX Oncology | SC TO-I/A: Third party tender offer statement (Amendment)
ALX Oncology | SCHEDULE 13G: Others
ALX Oncology | SCHEDULE 13G/A: Others
ALX Oncology | 4: Statement of changes in beneficial ownership of securities-Director Hemrajani Rekha
ALX Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Shelly
ALX Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Lettmann Jason
ALX Oncology | SC TO-I: Issuer tender offer statement
ALX Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Sandler Alan B.
ALX Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Capital LLC(0.0%),OrbiMed Advisors LLC(0.0%)
ALX Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Vivo Capital Fund IX, L.P.(3.4%),Vivo Capital IX, LLC(3.4%), etc.
ALX Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Cormorant Asset Management, LP(0%),Bihua Chen(0%)
ALX Oncology | 8-K: Current report
ALX Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(11.135%),Abigail P. Johnson(11.135%)
ALX Oncology | 8-K: ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology | 10-Q: Q3 2024 Earnings Report
ALX Oncology | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Millennium Management LLC(3.8%),Millennium Group Management LLC(3.8%), etc.
ALX Oncology | 8-K: Current report